A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

NCT01106651 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

716

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Canagliflozin 100 mg
DRUG: Canagliflozin 300 mg
DRUG: Antihyperglycemic agent(s)
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC